Apollomics, Inc. (NASDAQ:APLM) is seeing a significant increase in short interest

Apollomics, Inc. (NASDAQ:APLM – Get Free Report ) received a significant increase in short interest in July. As of July 31st, there was short interest totaling 394,600 shares, an increase of 637.6% from July 15th’s total of 53,500 shares. Based on an average trading volume of 1,090,000 shares, the short interest rate is currently 0.4 days. About 0.7% of the company’s shares are short sold.

Apollomics price performance

Shares of Apollomics stock opened at $0.16 on Tuesday. Apollomics has a 52 week low of $0.13 and a 52 week high of $5.45. The company’s fifty day moving average price is $0.20 and its two hundred day moving average price is $0.43.

Apollomics Institutional Trading

An institutional investor recently lifted its position in Apollomics shares. George Kaiser Family Foundation raised its stake in Apollomics, Inc. (NASDAQ:APLM – Free Report) by 2,585.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the period. Apollomics comprises about 0.0% of George Kaiser Family Foundation’s holdings, making the stock its 18th biggest holding. George Kaiser Family Foundation owned about 0.75% of Apollomics worth $141,000 as of its most recent SEC filing. 19.13% of shares are held by institutional investors.

The Wall Street analyst weighs in

Separately, HC Wainwright reduced their price objective on Apollomics from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th.

Check out our latest report on apollomics

Apollomics Company Profile

(Get a free report)

Apollomics, Inc, a clinical-stage biopharmaceutical company, is engaged in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s product portfolio includes Vebreltinib (APL-101), an orally active, highly selective c-Met inhibitor in Phase 2 clinical trials for the treatment of non-small cell lung cancer; APL-102, an orally active small molecule multiple tyrosine kinase inhibitor, which is in a phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate targeting ErbB1/2/4 signaling pathways that is in phase 1 dose-escalation clinical trials to treat brain cancers.

Featured stories

Get news and reviews for Apollomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Apollomics and related companies with MarketBeat.com’s FREE daily email newsletter.